Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells $76,850.00 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Peter Heerma sold 3,074 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total transaction of $76,850.00. Following the transaction, the insider now owns 127,634 shares in the company, valued at approximately $3,190,850. The trade was a 2.35 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Peter Heerma also recently made the following trade(s):

• On Wednesday, January 22nd, Peter Heerma sold 1,584 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.94, for a total value of $30,000.96.

Travere Therapeutics Stock Down 3.4 %

NASDAQ TVTX opened at $22.91 on Friday. The stock’s 50 day simple moving average is $19.22 and its 200 day simple moving average is $16.10. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $25.29. The firm has a market cap of $1.79 billion, a PE ratio of -5.04 and a beta of 0.72.

Wall Street Analyst Weigh In

A number of brokerages have commented on TVTX. HC Wainwright raised their price objective on Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, January 15th. Wells Fargo & Company raised Travere Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $9.00 to $27.00 in a research report on Monday, October 21st. Evercore ISI boosted their price target on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a report on Wednesday. Piper Sandler lifted their target price on shares of Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, November 14th. Finally, Scotiabank increased their price target on shares of Travere Therapeutics from $27.00 to $32.00 and gave the stock a “sector outperform” rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $27.77.

Institutional Trading of Travere Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sterling Capital Management LLC grew its holdings in Travere Therapeutics by 859.8% during the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company’s stock worth $41,000 after acquiring an additional 2,115 shares during the last quarter. R Squared Ltd bought a new stake in shares of Travere Therapeutics during the fourth quarter valued at approximately $53,000. CWM LLC increased its holdings in shares of Travere Therapeutics by 158.5% in the third quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after purchasing an additional 3,065 shares in the last quarter. Quarry LP acquired a new stake in shares of Travere Therapeutics in the third quarter valued at approximately $105,000. Finally, Ameritas Investment Partners Inc. lifted its holdings in Travere Therapeutics by 9.2% during the 4th quarter. Ameritas Investment Partners Inc. now owns 7,905 shares of the company’s stock worth $138,000 after buying an additional 667 shares in the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.